Xenon Pharmaceuticals Inc (XENE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Xenon Pharmaceuticals Inc (XENE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7556
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that discovers and develops therapeutics for patients suffering with neurological disorders. The company’s pipeline products include XEN1101, XEN901, XEN007 and GDC-0310. It discovers various validated drug targets through the study of rare human diseases with extreme traits, including channelopathies and diseases caused by mutations in ion channels. Xenon’s target treatment areas include lipoprotein lipase deficiency, cardiovascular diseases, dermatology, pain and dravet syndrome. The company partners with pharmaceutical companies to access development and commercial resources, and non-dilutive funding to validate the advancement of diverse pipeline. Xenon is headquartered in Burnaby, British Columbia, Canada.

Xenon Pharmaceuticals Inc (XENE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Xenon Acquires Milestones and Royalties Related to XEN1101 Program from Valeant Pharma 12
Xenon Pharmaceuticals Acquires Development and Commercialization Rights for XEN1101 from 1st Order 13
Partnerships 14
Medpace Enters into Amendment Agreement with Xenon Pharma 14
Xenon Pharma Extends Agreement with Genentech 15
Licensing Agreements 16
Xenon Pharma Enters into Licensing Agreement with Pharma CMO 16
Xenon Pharma Enters into Licensing Agreement with Pharmaceutical Company 17
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 18
Equity Offering 20
Xenon Pharma Raises USD63 Million in Public Offering of Shares 20
Xenon Pharma to Raise up to USD30 Million in Public Offering of Shares 22
Xenon Pharma Completes Public Offering of Shares for USD34.5 Million 23
Xenon Pharma Raises USD41.4 Million in IPO of Shares 25
Xenon Pharmaceuticals Inc – Key Competitors 27
Xenon Pharmaceuticals Inc – Key Employees 28
Xenon Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 07, 2018: Xenon Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 30
May 08, 2018: Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 33
Mar 07, 2018: Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update 35
Nov 07, 2017: Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 38
Aug 03, 2017: Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 40
May 09, 2017: Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 42
Mar 08, 2017: Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update 44
Corporate Communications 46
Mar 13, 2018: Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer 46
Clinical Trials 47
Sep 06, 2018: Xenon expands ion channel neurology pipeline with addition of XEN496, a “Phase 3 Ready” potassium channel modulator for the treatment of epilepsy 47
Oct 17, 2017: Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial 49
Jun 27, 2017: Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint 50
Jun 27, 2017: Xenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070 Phase 2b Clinical Trial in PHN 51
Other Significant Developments 52
Jan 08, 2018: Xenon Pharmaceuticals Outlines Key Milestones for 2018 52
Jan 08, 2017: Xenon Pharmaceuticals Outlines Key Milestones for 2017 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenon Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Xenon Acquires Milestones and Royalties Related to XEN1101 Program from Valeant Pharma 12
Xenon Pharmaceuticals Acquires Development and Commercialization Rights for XEN1101 from 1st Order 13
Medpace Enters into Amendment Agreement with Xenon Pharma 14
Xenon Pharma Extends Agreement with Genentech 15
Xenon Pharma Enters into Licensing Agreement with Pharma CMO 16
Xenon Pharma Enters into Licensing Agreement with Pharmaceutical Company 17
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 18
Xenon Pharma Raises USD63 Million in Public Offering of Shares 20
Xenon Pharma to Raise up to USD30 Million in Public Offering of Shares 22
Xenon Pharma Completes Public Offering of Shares for USD34.5 Million 23
Xenon Pharma Raises USD41.4 Million in IPO of Shares 25
Xenon Pharmaceuticals Inc, Key Competitors 27
Xenon Pharmaceuticals Inc, Key Employees 28
Xenon Pharmaceuticals Inc, Subsidiaries 29

List of Figures
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Xenon Pharmaceuticals Inc (XENE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Santander Private Bank:企業の戦略・SWOT・財務分析
    Santander Private Bank - Strategy, SWOT and Corporate Finance Report Summary Santander Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Mitobridge Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mitobridge Inc (Mitobridge), formerly Mitokyne, Inc. is a drug development company that discovers and develops small molecule therapeutics. The company offers products that enhance the mitochondrial functions. It develops therapies for rare diseases and then expand into more common diseases. …
  • DaChan Food (Asia) Limited:企業の戦略・SWOT・財務情報
    DaChan Food (Asia) Limited - Strategy, SWOT and Corporate Finance Report Summary DaChan Food (Asia) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Dufry AG (DUFN):企業の財務・戦略的SWOT分析
    Dufry AG (DUFN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Pine Cliff Energy Ltd (PNE):企業の財務・戦略的SWOT分析
    Summary Pine Cliff Energy Ltd (Pine Cliff) is an oil and gas company that offers exploration, production, and development of natural gas, crude oil, and natural gas liquids. The company operates through its core areas such as Edson Assets, Central Assets, and Southern Assets. It acquired Hatton prop …
  • Bilcare Ltd (526853):企業の財務・戦略的SWOT分析
    Bilcare Ltd (526853) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Green Cross Cell Corp (031390):企業の財務・戦略的SWOT分析
    Green Cross Cell Corp (031390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Tohoku Electric Power Company, Incorporated:企業の戦略・SWOT・財務分析
    Tohoku Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Tohoku Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Merit Medical Systems Inc (MMSI):企業の製品パイプライン分析
    Summary Merit Medical Systems Inc (Merit Medical) offers a range of single-use medical devices for interventional and diagnostic procedures. The company’s products include inflation devices and accessories, diagnostic and therapeutic catheters, diagnostic and hydrophilic products, thrombolytic cathe …
  • ABPA Holdings Ltd:企業の戦略的SWOT分析
    ABPA Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • St. Jude Children’s Research Hospital Inc-製薬・医療分野:企業M&A・提携分析
    Summary St. Jude Children’s Research Hospital Inc (St. Jude) is a healthcare service provider that offers research and clinical care services for children with catastrophic diseases. The hospital provides treatment programs such as brain tumors, leukemia, infectious diseases, immunodeficiency diseas …
  • Kyokuyo Co., Ltd.
    Kyokuyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kyokuyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • China Cinda Asset Management Co Ltd:企業のM&A・事業提携・投資動向
    China Cinda Asset Management Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Cinda Asset Management Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on …
  • Merafe Resources Ltd:企業の戦略・SWOT・財務分析
    Merafe Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Merafe Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Abg Sundal Collier Holding Asa
    Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report Summary Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • MAN SE:企業の戦略・SWOT・財務分析
    MAN SE - Strategy, SWOT and Corporate Finance Report Summary MAN SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Safaricom Ltd
    Safaricom Ltd - Strategy, SWOT and Corporate Finance Report Summary Safaricom Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • United Continental Holdings Inc:戦略・SWOT・企業財務分析
    United Continental Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary United Continental Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • LSIS Co Ltd (010120):企業の財務・戦略的SWOT分析
    LSIS Co Ltd (010120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Kuwait And Middle East Financial Investment Company (K.S.C.P.) (KMEFIC):企業の財務・戦略的SWOT分析
    Kuwait And Middle East Financial Investment Company (K.S.C.P.) (KMEFIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆